RXRX FY 2020 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+99.5% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$85M-2479.2% margin

Net Income

-$87M-2549.3% margin

EPS (Diluted)

$-0.52

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$52M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$299M

Total Liabilities

$505M

Stockholders' Equity

-$206M

Cash & Equivalents

$262M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+99.5%
Gross Profit	$3M	-$44M	+107.7%
Operating Income	-$85M	-$62M	-35.5%
Net Income	-$87M	-$63M	-39.2%